 Following receipt of a Pre-Assignment number from the FDA Jupiter Wellness requests Pre-IND meeting JUPITER, FL ACCESSWIRE August 23, 2021 Jupiter Wellness, Inc. NASDAQ:JUPW, a developer of enhanced skin care therapeutics and treatments focused on the endocannabinoid system today announced it has submitted a pre-IND Investigational New Drug meeting request with the U.S. Food and Drug Administration FDA in support of its JW-100 drug development program the treatment of patients with mild to moderate Eczema . The benefits of holding a pre-IND meeting are to receive early FDA feedback on proposed preclinical and clinical study plans confirming strategy for IND submission. 